Through sophisticated glycoconjugate technology, we enhance the immunogenic properties of vaccines, improving their efficacy against various pathogens. The conjugates are formed by the covalent combination of polysaccharides with proteins, working together to stimulate a stronger and more lasting immune response.

This technology uses nanoparticles as vectors for the targeted delivery of antigens for development of vaccines. The nanoparticles improve the presentation of the antigen to the immune system and can be used to construct more effective vaccines and targeted therapies against a variety of infectious diseases.

SAEPs are synthetic peptides specifically designed to neutralize bacterial endotoxins. This technology is crucial in the prevention and management of toxic reactions caused by the release of endotoxins during bacterial infections, offering a new therapeutic horizon in the battle against Gram-negative bacterial infections.

Endotoxoids are modified, non-toxic versions of endtoxins released by certain bacteria. In our strategy, endotoxoids are used to develop vaccines that, while lacking toxicity but retaining immunogenic capacity, are capable of stimulating the immune system to produce a protective response against the original pathogens.